<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470651</url>
  </required_header>
  <id_info>
    <org_study_id>C10953/6285</org_study_id>
    <nct_id>NCT01470651</nct_id>
  </id_info>
  <brief_title>Armodafinil for Patients Starting Hepatitis C Virus Treatment</brief_title>
  <official_title>Armodafinil for Patients Starting Hepatitis C Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Foundation for Mental Hygiene, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is one of the most common side effects of the treatment of hepatitis C infection with
      pegylated interferon and ribavirin, and is a major cause of treatment discontinuation.
      Armodafinil is an FDA approved stimulant medication for the treatment of narcolepsy and
      shift-work sleep disorder. This is a randomized placebo controlled study to determine whether
      patients assigned to armodafinil have fewer missed doses, dose reductions or treatment
      discontinuation due to side effects in the first 12 weeks of treatment for hepatitis C
      infection than do placebo patients. Placebo patients are offered 14 weeks of open label
      armodafinil after Week 12.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four million Americans have chronic hepatitis C (HCV), and 30% of HIV+ patients are
      co-infected with HCV. Until May 2011, the standard treatment for HCV was the combination of
      alpha interferon (injected weekly) and ribavirin (daily pills) (IFN/RBV) for 48 weeks in
      order to achieve sustained virologic remission (cure). HCV treatment initiation was low,
      often because of concern about severe treatment side effects as well as high rates of
      virologic failure. Among the minority of medically eligible HCV+ patients (with or without
      co-morbid HIV/AIDS) who actually began treatment with IFN/RBV, side effects cause substantial
      attrition (about 20% by Week 12, 40% by Week 24). The most common adverse events are flu-like
      symptoms, of which fatigue is most prominent. Depressed mood is also common (mostly somatic
      symptoms).

      Two new medications, telaprevir and boceprevir (protease inhibitors) have been successful in
      treatment of HCV in clinical trials, and both were approved by the FDA for those patients
      with genotype 1 HCV, and are marketed as of May 2011. One of the new drugs will be added to
      the current regimen for genotype 1 infection. Because both drugs are protease inhibitors,
      which develop rapid resistance when administered alone, they must be added to the current
      standard of care rather than replace it. This is expected to vastly increase willingness of
      doctors to recommend treatment, and for patients to agree to treatment. The investigators
      expect that most hepatologists will recommend, and patients agree to the addition of one of
      these medications from now on. However, it should be noted that both commonly cause fatigue
      if it isn't already present because of HCV itself, or peginterferon or ribavirin. The major
      adverse event associated with telaprevir is rash, and with boceprevir, anemia.

      This is a 14-week placebo controlled double blind trial of armodafinil for patients about to
      begin HCV treatment, starting armodafinil or placebo 2 weeks prior to initiation of HCV
      treatment. Patients are recruited from the hepatology clinics at the respective sites.
      Randomization is 1:1. Placebo patients who continue HCV treatment are offered 14 weeks of
      armodafinil starting at Week 12 of HCV treatment when the armodafinil/placebo blind is
      broken.

      Patients will be seen weekly for the first 4 weeks to titrate armodafinil dose and manage
      side effects, if any, and then biweekly, with telephone contact on the intervening weeks
      through Week 12. After that, monthly telephone calls through Week 24 will be conducted with
      patients randomized to armodafinil, and biweekly visits with placebo patients beginning
      armodafinil at Week 12.

      The primary outcome measures concern non-adherence to INF/RBV treatment: 1) missed doses; 2)
      dose reductions, and 3) attrition due to side effects. Secondary outcomes include ratings of
      fatigue on the Fatigue Severity Scale, depression on the Patient Health Questionnaire
      (PHQ-9), and quality of life on the Endicott Quality of Life Enjoyment and Satisfaction
      Questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    European Medicines Agency issued a drug/drug interaction: sofosbuvir/modafinil
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to Medications Form</measure>
    <time_frame>HCV medication adherence reported at 12 weeks</time_frame>
    <description>The Medication Adherence Form was designed to assess any HCV medication dosing changes, including discontinuation, and the reasons for the changes. The form asks specifically about the HCV medications: pegylated interferon, ribavirin and Incivek (or Victrelis), as well as the study medication, armodafinil.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>Biweekly for the first month, monthly thereafter</time_frame>
    <description>Fatigue Severity Scale is a 9-item scale measures the impact of fatigue on everyday functioning (e.g. &quot;fatigue interferes with my work, family or social life&quot;). Response format is a 7-point Likert scale of agreement with a 1-week time frame. Total score is the sum of item scores and ranges from 9 to 63 points, with higher scores indicating greater fatigue. A score greater than 40 is considered to be a clinically significant level of fatigue. Scores on the scale correlate highly with other measures of fatigue, is sensitive to change, and is routinely used in studies of modafinil/armodafinil.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive pill, matched to look like active medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>50mg - 250mg pills, taken each morning, for 14 weeks</description>
    <arm_group_label>Armodafinil</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Inactive pill, matched to look like active medication</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV+ patients medically cleared for IFN/RBV treatment -HIV+ or HIV-

          -  Speaks English

          -  Able and willing to give informed consent

          -  Fecund women: use barrier method of contraception

        Exclusion Criteria:

          -  Untreated and uncontrolled hypertension

          -  Left ventricular hypertrophy

          -  Currently taking stimulant medication

          -  Uncontrolled mental health problems including: MDD, suicidal or homicidal ideation,
             bipolar disorder, or schizophrenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Weiss, Ph.D., MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen J. Ferrando, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Weill Cornell Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Foundation for Mental Hygiene, Inc.</investigator_affiliation>
    <investigator_full_name>Judith G. Rabkin, PhD</investigator_full_name>
    <investigator_title>Research Scientist VI</investigator_title>
  </responsible_party>
  <keyword>HCV+</keyword>
  <keyword>HCV treatment</keyword>
  <keyword>Fatigue</keyword>
  <keyword>patients starting alpha interferon/ribavirin treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil</title>
          <description>Active medication
Armodafinil: 50mg - 250mg pills, taken each morning, for 14 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Inactive pill, matched to look like active medication
Placebo Comparator: Inactive pill, matched to look like active medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil</title>
          <description>Active medication
Armodafinil: 50mg - 250mg pills, taken each morning, for 14 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Inactive pill, matched to look like active medication
Placebo Comparator: Inactive pill, matched to look like active medication</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.77" lower_limit="28" upper_limit="65"/>
                    <measurement group_id="B2" value="57.23" lower_limit="36" upper_limit="70"/>
                    <measurement group_id="B3" value="55.5" lower_limit="28" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence to Medications Form</title>
        <description>The Medication Adherence Form was designed to assess any HCV medication dosing changes, including discontinuation, and the reasons for the changes. The form asks specifically about the HCV medications: pegylated interferon, ribavirin and Incivek (or Victrelis), as well as the study medication, armodafinil.</description>
        <time_frame>HCV medication adherence reported at 12 weeks</time_frame>
        <population>Not all patients were given all medications, subjects are not factored in if they were not told to take a given drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>Active medication
Armodafinil: 50mg - 250mg pills, taken each morning, for 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Inactive pill, matched to look like active medication
Placebo Comparator: Inactive pill, matched to look like active medication</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Medications Form</title>
          <description>The Medication Adherence Form was designed to assess any HCV medication dosing changes, including discontinuation, and the reasons for the changes. The form asks specifically about the HCV medications: pegylated interferon, ribavirin and Incivek (or Victrelis), as well as the study medication, armodafinil.</description>
          <population>Not all patients were given all medications, subjects are not factored in if they were not told to take a given drug.</population>
          <units>Percentage of doses missed</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pegylated interferon</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1.74" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ribavirin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="3.24" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incivek (or Victrelis)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="3.06"/>
                    <measurement group_id="O2" value="2.88" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Armodafinil or Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="9.34"/>
                    <measurement group_id="O2" value="8.02" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Severity Scale (FSS)</title>
        <description>Fatigue Severity Scale is a 9-item scale measures the impact of fatigue on everyday functioning (e.g. “fatigue interferes with my work, family or social life”). Response format is a 7-point Likert scale of agreement with a 1-week time frame. Total score is the sum of item scores and ranges from 9 to 63 points, with higher scores indicating greater fatigue. A score greater than 40 is considered to be a clinically significant level of fatigue. Scores on the scale correlate highly with other measures of fatigue, is sensitive to change, and is routinely used in studies of modafinil/armodafinil.</description>
        <time_frame>Biweekly for the first month, monthly thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>Active medication
Armodafinil: 50mg - 250mg pills, taken each morning, for 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Inactive pill, matched to look like active medication
Placebo Comparator: Inactive pill, matched to look like active medication</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Severity Scale (FSS)</title>
          <description>Fatigue Severity Scale is a 9-item scale measures the impact of fatigue on everyday functioning (e.g. “fatigue interferes with my work, family or social life”). Response format is a 7-point Likert scale of agreement with a 1-week time frame. Total score is the sum of item scores and ranges from 9 to 63 points, with higher scores indicating greater fatigue. A score greater than 40 is considered to be a clinically significant level of fatigue. Scores on the scale correlate highly with other measures of fatigue, is sensitive to change, and is routinely used in studies of modafinil/armodafinil.</description>
          <units>FSS score (out of 63)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.29" spread="17.17"/>
                    <measurement group_id="O2" value="26.90" spread="15.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.71" spread="16.16"/>
                    <measurement group_id="O2" value="36.60" spread="17.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.14" spread="17.58"/>
                    <measurement group_id="O2" value="38.90" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.00" spread="20.93"/>
                    <measurement group_id="O2" value="40.00" spread="18.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.71" spread="20.15"/>
                    <measurement group_id="O2" value="38.40" spread="16.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline readings were collected two weeks before randomization to placebo or Armodafinil until 16 weeks after randomization. Measurements weekly until post-randomization week 12 at which point they were taken every other week.</time_frame>
      <desc>Side effects form listed: Nervousness, Irritability, Headaches, Nausea, Insomnia, Shortness of Breath, Difficulty Concentrating, Appetite/weight loss, Taste change, Dry mouth, Diarrhea, muscle aches, rash, fever, rectal pain, and two &quot;other&quot; fields. Side effect onset was defined as a two point increase (on a 5 point scale) from baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil</title>
          <description>Active medication
Armodafinil: 50mg - 250mg pills, taken each morning, for 14 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Inactive pill, matched to look like active medication
Placebo Comparator: Inactive pill, matched to look like active medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rectal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Altered Sense of Smell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Allergy Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Plantar Fascitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Appetite or weight change</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Taste Change</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tingling Feeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Difficulty in Concentration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Emotional instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is difficult to attribute side effects to Armodafinil or placebo given patients were undergoing Hepatitis C Treatment throughout the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Judith Rabkin</name_or_title>
      <organization>New York State Psychiatric Institute-Research Foundation for Mental Hygene</organization>
      <phone>646-774-8075</phone>
      <email>jgr1@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

